1Pepys MB. C - reactive protein fifty years on [ J ]. Lancet, 1981,21: 653.
2Volanakis JE. Human C - reactive protein: expression, structure and function [ J ]. Mol lmmunol, 2001,38 ( 2 - 3 ) : 189.
3Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes : results of the prospective population - based European Prospective Investigation into Cancer and Nutrition (EPIC) - Potsdam Study [ J ]. Diabetes, 2003,52(3) :812.
4Pickup JC,Mattock MB,Chusney GD,et al. NIDDM as a disease of the innate immune system : association of acute - phase reactants and interleukin- 6 with metabolic syndrome X[ J ]. Diabetologia, 1997,40( 11 ) : 1286.
5Pradhan AD, Manson JE, Rifai N, et al. C - reactive protein,interleukin 6, and risk of developing type 2 diabetes meUitus [ J ]. JAMA,2001,286 : 327.
6Reynold GD, Vance RP. C - reactive protein immunohistochemical localization in normal and atherosclerotic human aortas [J]. Arch Pathol Lab Med,1987,111 (3) :265.
7Torzewski J, Bowyer DE, Torzewski M, et al. C - reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries [ J ]. Arterioscler Thromb Vase Biol, 1998,18 ( 9 ) : 1386.
8Woodman RJ,Watts GF,Puddey IB, et al. Leukocyte count and vascular function in type 2 diabetic subjects with treated hypertension [ J ]. Atherosclerosis, 2002,163 ( 1 ) : 175.
